Please use this identifier to cite or link to this item:
|Title:||TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II.|
|Authors:||Siva, Shankar;Chesson, Brent;Bressel, Mathias;Pryor, David;Higgs, Braden;Reynolds, Hayley M;Hardcastle, Nicholas;Montgomery, Rebecca;Vanneste, Ben;Khoo, Vincent;Ruben, Jeremy;Lau, Eddie;Hofman, Michael S;De Abreu Lourenco, Richard;Sridharan, Swetha;Brook, Nicholas R;Martin, Jarad;Lawrentschuk, Nathan L;Kron, Tomas;Foroudi, Farshad|
|Affiliation:||Peter MacCallum Cancer Centre, 305 Grattan Street Melbourne, Melbourne, 3000, Australia|
Princess Alexandra Hospital, Brisbane, QLD, Australia
Trans Tasman Radiation Oncology Group (TROG), Waratah, Australia
Centre for Health Economics Research and Evaluation, University of Technology Sydney, Sydney, Australia
Austin Health, Heidelberg, Victoria, Australia
Alfred Health and Monash University, 55 Commercial Rd, Melbourne, 3004, Australia
University of Adelaide, Royal Adelaide Hospital, Adelaide, South Australia, Australia
Department of Radiation Oncology, Austin Health, Heidelberg, Victoria, Australia
Peter MacCallum Cancer Centre, 305 Grattan Street Melbourne, Melbourne, 3000, Australia
University of Melbourne, Royal Parade, Parkville, 8006, Australia
Calvary Mater Newcastle, Newcastle, NSW, Australia
MAASTRO Clinic, Maastricht, The Netherlands..
Royal Marsden Hospital, London, UK..
|Citation:||BMC cancer 2018; 18(1): 1030|
|Abstract:||Stereotactic ablative body radiotherapy (SABR) is a non-invasive alternative to surgery to control primary renal cell cancer (RCC) in patients that are medically inoperable or at high-risk of post-surgical dialysis. The objective of the FASTRACK II clinical trial is to investigate the efficacy of SABR for primary RCC. FASTRACK II is a single arm, multi-institutional phase II study. Seventy patients will be recruited over 3 years and followed for a total of 5 years. Eligible patients must have a biopsy confirmed diagnosis of primary RCC with a single lesion within a kidney, have ECOG performance ≤2 and be medically inoperable, high risk or decline surgery. Radiotherapy treatment planning is undertaken using four dimensional CT scanning to incorporate the impact of respiratory motion. Treatment must be delivered using a conformal or intensity modulated technique including IMRT, VMAT, Cyberknife or Tomotherapy. The trial includes two alternate fractionation schedules based on tumour size: for tumours ≤4 cm in maximum diameter a single fraction of 26Gy is delivered; and for tumours > 4 cm in maximum diameter 42Gy in three fractions is delivered. The primary outcome of the study is to estimate the efficacy of SABR for primary RCC. Secondary objectives include estimating tolerability, characterising overall survival and cancer specific survival, estimating the distant failure rate, describing toxicity and renal function changes after SABR, and assessment of cost-effectiveness of SABR compared with current therapies. The present study design allows for multicentre prospective validation of the efficacy of SABR for primary RCC that has been observed from prior single institutional and retrospective series. The study also allows assessment of treatment related toxicity, overall survival, cancer specific survival, freedom from distant failure and renal function post therapy. Clinicaltrials.gov NCT02613819 , registered Nov 25th 2015.|
|Type:||Clinical Trial, Phase II|
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.